Alexander B. Olawaiye, MD

Alexander B. Olawaiye, MD, is a professor in the Department of Obstetrics & Reproductive Sciences at the University of Pittsburgh, as well as the director of gynecologic cancer research at Magee-Women’s Hospital of the University of Pittsburgh Medical Center

Articles

Dr Olawaiye on Phase 2 Data With Relacorilant and Nab-Paclitaxel in Ovarian Cancer

July 7th 2025

Alexander B. Olawaiye, MD, discusses data with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer that led to the phase 3 ROSELLA trial.

Dr Olawaiye on Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

June 25th 2025

Alexander B. Olawaiye, MD, discusses clinical implications of data from the phase 3 ROSELLA trial.

ROSELLA: A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72)

June 20th 2025

Alexander Olawaiye, MD, presents results from the phase 3 ROSELLA trial, in which relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, with a manageable safety profile.

Dr Olawaiye on Data for Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

June 2nd 2025

Alexander Olawaiye, MD, discusses the efficacy and safety of relacorilant plus nab-Paclitaxel in platinum-resistant ovarian cancer.

Dr Olawaiye on the Potential Role of Afuresertib Plus Paclitaxel in pAKT-Expressing Platinum-Resistant Ovarian Cancer

March 31st 2025

Alexander B. Olawaiye, MD, discusses future research that could inform the use of afuresertib plus paclitaxel in platinum-resistant ovarian cancer.

Dr. Olawaiye on How to Address Disparities in Cancer Care

April 29th 2022

Alexander B. Olawaiye, MD, discusses how to address disparities in cancer care.

Dr. Olawaiye on Front Line Treatment Sequencing Considerations in Ovarian Cancer

March 15th 2022

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

Dr. Olawaiye on the Social and Biological Determinants of Disparities in Women’s Cancer

March 12th 2022

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

Dr. Olawaiye on Investigating Balstilimab Plus Zalifrelimab in Gynecologic Cancers

February 1st 2022

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

Dr. Olawaiye on the Role of Surgery in Newly Diagnosed Ovarian Cancer

April 3rd 2020

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

x